Drug Trial Radar · NCT04975308
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
874
Actual
Start
Oct 4, 2021
Primary completion
Jun 24, 2024
Study completion Aug 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jul 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.
Conditions
- Breast Neoplasms
- Neoplasm Metastasis
Interventions
ImlunestrantDrug
Administered orally.
ExemestaneDrug
Administered orally.
FulvestrantDrug
Administered IM.
AbemaciclibDrug
Administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)
- Investigator-assessed PFS (Between Arm C and Arm A)Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)
- Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B)Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)
Locations
243 sites in 22 countries. Site status is shown where the registry gives one.
Ironwood Cancer & Research Centers
Chandler, Arizona
Banner MD Anderson Cancer Center
Gilbert, Arizona
Marin Cancer Care
Greenbrae, California
University of California Davis (UC Davis) Comprehensive Cancer Center
Sacramento, California
Sharp Memorial Hospital
San Diego, California
Banner MD Anderson Cancer Center at McKee Medical Center
Loveland, Colorado
Clermont Oncology Center
Clermont, Florida
University of Florida College of Medicine
Gainesville, Florida
Mid Florida Hematology and Oncology Center
Orange City, Florida
Florida Cancer Specialists
Sarasota, Florida
Florida Cancer Specialists
St. Petersburg, Florida
Kaiser Permanente Moanalua Medical Center
Honolulu, Hawaii
University of Chicago Medical Center
Chicago, Illinois
NorthShore University HealthSystem - Evanston Hospital
Evanston, Illinois
IU Health Ball Memorial Hospital, Inc.
Muncie, Indiana
The University of Louisville, James Graham Brown Cancer Center
Louisville, Kentucky
Jackson Oncology Associates, PLLC
Jackson, Mississippi
Care Access - Clifton
Clifton, New Jersey
Memorial Sloan Kettering - Bergen
Montvale, New Jersey
Columbia University Medical Center
New York, New York
University of North Carolina Medical Center
Chapel Hill, North Carolina
Aultman Hospital
Canton, Ohio
Mercy Health - St. Vincent Medical Center
Toledo, Ohio
Avera Cancer Institute Sioux Falls
Sioux Falls, South Dakota
Florida Cancer Specialists
Nashville, Tennessee
The Mark H Zangmeister Cancer Center
Nashville, Tennessee
USO - Texas Oncology - Allen
Allen, Texas
Texas Oncology - Dallas Presbyterian Hospital
Dallas, Texas
Willamette Valley Cancer Institute & Research Ctr.
Houston, Texas
Texas Oncology - Carrollton
Lewisville, Texas
Texas Oncology - Denison
The Woodlands, Texas
Texas Oncology - Paris
The Woodlands, Texas
Blue Ridge Cancer Care
The Woodlands, Texas
Broome Oncology
The Woodlands, Texas
Minnesota Oncology/Hematology PA
The Woodlands, Texas
Texas Oncology - Carrollton
The Woodlands, Texas
Texas Oncology - McKinney
The Woodlands, Texas
Texas Oncology - Medical City Dallas
The Woodlands, Texas
Texas Oncology - Methodist Charlton Cancer Center
The Woodlands, Texas
Texas Oncology - San Antonio Medical Center
The Woodlands, Texas
Showing 40 of 243 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.